Alkermes commences trial of nemvaleukin monotherapy for melanoma
Source: Verdict Media Limited, April 2021
Alkermes has initiated a global Phase II ARTISTRY-6 trial of its lead immuno-oncology candidate nemvaleukin alfa in melanoma patients who have previously received anti-PD-(L)1 therapy.
Nemvaleukin is a novel, investigational engineered interleukin-2 (IL-2) variant immunotherapy.
